Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LX1031: Phase Ib data

In a dose-escalation Phase Ib trial, LX1031 was well tolerated. At the

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE